KM 501
Alternative Names: KM-501; XZP-KM501Latest Information Update: 29 Dec 2023
At a glance
- Originator Xuanzhu Biopharmaceutical
- Class Antineoplastics; Bispecific antibodies; Drug conjugates
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer; Colorectal cancer; Gastric cancer; Solid tumours
Most Recent Events
- 28 Dec 2023 Innovent Biologics and Xuanzhu Biopharmaceutical agree to co-develop combination of KM 501 and Sintilimab in China for Solid tumours
- 28 Dec 2023 Phase-I clinical trials in Breast cancer in China prior to December 2023 (Parenteral) (Xuanzhu Biopharmaceutical, December 2023)
- 28 Dec 2023 Phase-I clinical trials in Colorectal cancer in China prior to December 2023 (Parenteral) (Xuanzhu Biopharmaceutical, December 2023)